89 related articles for article (PubMed ID: 19912990)
1. Prevention of intracellular degradation of I2020T mutant LRRK2 restores its protectivity against apoptosis.
Ohta E; Kubo M; Obata F
Biochem Biophys Res Commun; 2010 Jan; 391(1):242-7. PubMed ID: 19912990
[TBL] [Abstract][Full Text] [Related]
2. Dominant-negative effects of LRRK2 heterodimers: a possible mechanism of neurodegeneration in Parkinson's disease caused by LRRK2 I2020T mutation.
Ohta E; Kawakami F; Kubo M; Obata F
Biochem Biophys Res Commun; 2013 Jan; 430(2):560-6. PubMed ID: 23220480
[TBL] [Abstract][Full Text] [Related]
3. I(2020)T leucine-rich repeat kinase 2, the causative mutant molecule of familial Parkinson's disease, has a higher intracellular degradation rate than the wild-type molecule.
Ohta E; Katayama Y; Kawakami F; Yamamoto M; Tajima K; Maekawa T; Iida N; Hattori S; Obata F
Biochem Biophys Res Commun; 2009 Dec; 390(3):710-5. PubMed ID: 19833102
[TBL] [Abstract][Full Text] [Related]
4. The mouse/human cross-species heterodimer of leucine-rich repeat kinase 2: possible significance in the transgenic model mouse of Parkinson's disease.
Miyajima T; Ohta E; Kawada H; Maekawa T; Obata F
Neurosci Lett; 2015 Feb; 588():142-6. PubMed ID: 25562633
[TBL] [Abstract][Full Text] [Related]
5. Evidence that the LRRK2 ROC domain Parkinson's disease-associated mutants A1442P and R1441C exhibit increased intracellular degradation.
Greene ID; Mastaglia F; Meloni BP; West KA; Chieng J; Mitchell CJ; Gai WP; Boulos S
J Neurosci Res; 2014 Apr; 92(4):506-16. PubMed ID: 24375786
[TBL] [Abstract][Full Text] [Related]
6. LRRK2 I2020T mutation is associated with tau pathology.
Ujiie S; Hatano T; Kubo S; Imai S; Sato S; Uchihara T; Yagishita S; Hasegawa K; Kowa H; Sakai F; Hattori N
Parkinsonism Relat Disord; 2012 Aug; 18(7):819-23. PubMed ID: 22525366
[TBL] [Abstract][Full Text] [Related]
7. LRRK2 directly phosphorylates Akt1 as a possible physiological substrate: impairment of the kinase activity by Parkinson's disease-associated mutations.
Ohta E; Kawakami F; Kubo M; Obata F
FEBS Lett; 2011 Jul; 585(14):2165-70. PubMed ID: 21658387
[TBL] [Abstract][Full Text] [Related]
8. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity.
Gloeckner CJ; Kinkl N; Schumacher A; Braun RJ; O'Neill E; Meitinger T; Kolch W; Prokisch H; Ueffing M
Hum Mol Genet; 2006 Jan; 15(2):223-32. PubMed ID: 16321986
[TBL] [Abstract][Full Text] [Related]
9. I2020T mutant LRRK2 iPSC-derived neurons in the Sagamihara family exhibit increased Tau phosphorylation through the AKT/GSK-3β signaling pathway.
Ohta E; Nihira T; Uchino A; Imaizumi Y; Okada Y; Akamatsu W; Takahashi K; Hayakawa H; Nagai M; Ohyama M; Ryo M; Ogino M; Murayama S; Takashima A; Nishiyama K; Mizuno Y; Mochizuki H; Obata F; Okano H
Hum Mol Genet; 2015 Sep; 24(17):4879-900. PubMed ID: 26056228
[TBL] [Abstract][Full Text] [Related]
10. Leucine-rich repeat kinase 2 mutants I2020T and G2019S exhibit altered kinase inhibitor sensitivity.
Reichling LJ; Riddle SM
Biochem Biophys Res Commun; 2009 Jun; 384(2):255-8. PubMed ID: 19397894
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of familial parkinson mutations in LRRK2 revealed by a systematic analysis of autophosphorylation.
Kamikawaji S; Ito G; Sano T; Iwatsubo T
Biochemistry; 2013 Sep; 52(35):6052-62. PubMed ID: 23924436
[TBL] [Abstract][Full Text] [Related]
12. The G2385R risk factor for Parkinson's disease enhances CHIP-dependent intracellular degradation of LRRK2.
Rudenko IN; Kaganovich A; Langston RG; Beilina A; Ndukwe K; Kumaran R; Dillman AA; Chia R; Cookson MR
Biochem J; 2017 Apr; 474(9):1547-1558. PubMed ID: 28320779
[TBL] [Abstract][Full Text] [Related]
13. Apoptotic mechanisms in mutant LRRK2-mediated cell death.
Iaccarino C; Crosio C; Vitale C; Sanna G; Carrì MT; Barone P
Hum Mol Genet; 2007 Jun; 16(11):1319-26. PubMed ID: 17409193
[TBL] [Abstract][Full Text] [Related]
14. The Parkinson disease-linked LRRK2 protein mutation I2020T stabilizes an active state conformation leading to increased kinase activity.
Ray S; Bender S; Kang S; Lin R; Glicksman MA; Liu M
J Biol Chem; 2014 May; 289(19):13042-53. PubMed ID: 24695735
[TBL] [Abstract][Full Text] [Related]
15. Leucine-rich repeat kinase 2 associates with lipid rafts.
Hatano T; Kubo S; Imai S; Maeda M; Ishikawa K; Mizuno Y; Hattori N
Hum Mol Genet; 2007 Mar; 16(6):678-90. PubMed ID: 17341485
[TBL] [Abstract][Full Text] [Related]
16. LRRK2 mutation in familial Parkinson's disease in a Taiwanese population: clinical, PET, and functional studies.
Lin CH; Tzen KY; Yu CY; Tai CH; Farrer MJ; Wu RM
J Biomed Sci; 2008 Sep; 15(5):661-7. PubMed ID: 18523869
[TBL] [Abstract][Full Text] [Related]
17. LRRK2 enhances oxidative stress-induced neurotoxicity via its kinase activity.
Heo HY; Park JM; Kim CH; Han BS; Kim KS; Seol W
Exp Cell Res; 2010 Feb; 316(4):649-56. PubMed ID: 19769964
[TBL] [Abstract][Full Text] [Related]
18. [Advance of the study on LRRK2 gene in Parkinson's disease].
Zhang Y; Chen S
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Dec; 25(6):657-9. PubMed ID: 19065525
[TBL] [Abstract][Full Text] [Related]
19. The LRRK2 I2012T, G2019S and I2020T mutations are not common in patients with essential tremor.
Deng H; Le W; Davidson AL; Xie W; Jankovic J
Neurosci Lett; 2006 Oct; 407(2):97-100. PubMed ID: 16939701
[TBL] [Abstract][Full Text] [Related]
20. The I2020T Leucine-rich repeat kinase 2 transgenic mouse exhibits impaired locomotive ability accompanied by dopaminergic neuron abnormalities.
Maekawa T; Mori S; Sasaki Y; Miyajima T; Azuma S; Ohta E; Obata F
Mol Neurodegener; 2012 Apr; 7():15. PubMed ID: 22534020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
